Every year, the race begins anew. Scientists scramble to track mutating viruses, pharmaceutical companies reformulate ...

Moderna voluntarily pressed pause on its request to license its vaccine candidate, mRNA-1083 — which combines vaccines for seasonal influenza and covid and is intended for people over 50 — until it ...

Overview of RNA Therapeutics MarketThe Global RNA Therapeutics Market is valued at USD 10.9 Billion in 2024 and is projected ...

This week, mRNA vaccines are set to face intense scrutiny from critics in Congress. Here's an explainer of how we know they are safe and effective.